Effectiveness and Tolerability of Ipilimumab: Experiences from 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

Journal of Immunotherapy

Volumn 37, Issue 7, 2014, Pages 374-381

  Eigentler, Thomas K ^a   Schlaak, Max ^b   Hassel, Jessica C ^c   Loquai, Carmen ^d   Stoffels, Ingo ^e   Gutzmer, Ralf ^f   Pätzold, Sylvie ^g   Mohr, Peter ^h   Keller, Ulrich ⁱ   Starz, Hans ^j   Ulrich, Jens ^k   Tsianakas, Athanasios ^l   Kähler, Katharina ^m   Hauschild, Axel ^m   Janssen, Eva ⁿ   Schuler Thurner, Beatrice ^o   Weide, Benjamin ^a   Garbe, Claus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h Elbe Kliniken   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j Department of Dermatology Zentralklinikum Augsburg ^*  (Germany)

^k Klinikum Dorothea Christiane Erxleben Quedlinburg gGmbH   (Germany)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o UNIVERSITY HOSPITAL ERLANGEN   (Germany)

more..

Author keywords

active immunotherapy; compassionate use; CTLA 4 antigen; ipilimumab; melanoma; treatment outcome

Indexed keywords

IPILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER CONTROL; CEREBROVASCULAR ACCIDENT; COLITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERMANY; HEPATITIS; HUMAN; HYPONATREMIA; HYPOPHYSITIS; INFLAMMATION; JEJUNUM ULCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENINGITIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREATITIS; PRIORITY JOURNAL; RASH; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; METASTASIS; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84906079247     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000046     Document Type: Article

References (26)

1. Berger ML, Dreyer N, Anderson F, et al. Prospective observational studies to assess comparative effectiveness: The ISPOR good research practices task force report. Value Health. 2012;15:217-230
2. Kleijnen S, George E, Goulden S, et al. Relative effectiveness assessment of pharmaceuticals: Similarities and differences in 29 jurisdictions. Value Health. 2012;15:954-960
3. Hanaizi Z, van Zwieten-Boot B, Calvo G, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2012;48:237-242
4. European Medicines Agency, Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. 2004:67-128. Available at http://www.ema.euro pa.eu/docs/en-GB/document-library/Regulatory-and-procedural- guideline/2009/10/WC500004481.pdf
5. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206
6. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214
7. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: Comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 2003;33:533-537
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216
9. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009;15: 7412-7420
10. Delyon J, Mateus C, Lefeuvre D, et al. Experience in Daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24:1697-1703
11. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767-1775
12. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723
13. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-update 2012. Eur J Cancer. 2012;48:2375-2390
14. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol. 2012;13:459-465
15. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J Clin Oncol. 2006;24:2283-2289
16. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053
17. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-Associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688
18. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598
19. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956
20. Bouwhuis MG, Suciu S, Collette S, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst. 2009;101: 869-877
21. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718
22. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: Long-Term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-2047
23. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24: 2174-2180
24. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745
25. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119: 1675-1682
26. Korn EL, Liu PY, Lee SJ, et al. Meta-Analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534